Purple Biotech Unveils CAPTN-3 Cancer Therapy
Purple Biotech Regains Nasdaq Compliance
HC Wainwright & Co. Maintains Buy on Purple Biotech, Adjusts Price Target To $33 (1-20 Reverse Stock Split)
H.C. Wainwright Maintains Purple Biotech(PPBT.US) With Buy Rating, Cuts Target Price to $33
H.C. Wainwright analyst Emily Bodnar maintains $Purple Biotech(PPBT.US)$ with a buy rating, and adjusts the target price from $200 to $33.According to TipRanks data, the analyst has a success rate
Purple Biotech Says Pancreatic Cancer Study Data Shows CM24 With Nivolumab and Chemo Improves Survival
Purple Biotech Reveals Optimistic Cancer Treatment Data
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Purple Biotech To Carry Out 1-for-20 Reverse Stock Split On September 17th, 2024
September 12th (Eastern Time) - $Purple Biotech(PPBT.US)$ is about to implement a 1-for-20 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from September 17th,
Purple Biotech Plans To Change Ratio Of ADS To Ordinary Shares To ADS Ratio Of 1 ADS Representing 200 Ordinary Shares
Analysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Aligos Therapeutics (ALGS)
Purple Biotech Targets Key Oncology Milestones
Purple Biotech Is Maintained at Buy by HC Wainwright & Co.
Express News | Purple Biotech Ltd : H.c. Wainwright Cuts Target Price to $8 From $10
Purple Biotech Reveals Promising CM24 Study Results
Purple Biotech 2Q Net $2.42M >PPBT
Purple Biotech 2Q EPS 9c >PPBT
Purple Biotech CFO Resigns for New Opportunities
Purple Biotech Gets Extension to Regain Nasdaq Compliance
Purple Biotech Receives Extension From Listing Qualifications Department Of Nasdaq To Regain Compliance With Minimum $1.00 Bid Price Requirement
Purple Biotech Receives Extension to Regain Compliance With the Nasdaq's Minimum Bid Price Rule